SHINE Technologies announced on January 2 that it has completed its acquisition of Lantheus‘ Single Photon Emission Computed Tomography (SPECT) business, including the North Billerica, Massachusetts SPECT manufacturing facility and its portfolio of diagnostic radiopharmaceuticals.
The SPECT facility has manufactured TechneLite® (Technetium Tc 99m Generator) for 55 years, serving hospitals and imaging centers across North America. The product portfolio also includes SPECT imaging agents Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection) and NEUROLITE® (Kit for the Preparation of Technetium Tc99m Bicisate for Injection), as well as Xenon Xe-133 Gas for pulmonary imaging. These products are used in millions of diagnostic imaging procedures annually for cardiac, pulmonary, thyroid, bladder and other applications.
Headquartered in Janesville, Wisconsin, SHINE Technologies is an industry leader in next-generation fusion, developing fusion-based technology that combines safety, cost-efficiency and environmental responsibility. SHINE has commercialized fusion across multiple applications, including neutron testing markets such as neutron radiography, radiation-effects testing and fusion material research. It has commercialized and is scaling its proprietary medical isotope production processes, supplying radioisotopes essential for procedures including diagnosing heart disease and cancer as well as cancer therapy.
The acquisition integrates manufacturing expertise, customer relationships and established market position into SHINE’s nuclear medicine business. Financial terms of the deal were not disclosed.
SHINE also announced that Michael Rossi will join the company as CEO of SHINE SPECT USA, LLC following the transaction. Most recently, Rossi served as President and CEO of Y-mAbs Therapeutics, which was acquired by SERB Pharmaceuticals in August 2025.
According to data captured in the LevinPro HC database, this transaction marks the first Laboratories, MRI and Dialysis transaction of the year. Throughout all of 2025, there were 137 Laboratories, MRI and Dialysis transactions, 72 of them in the diagnostic subsector.
